HMG-CoA reductase inhibitors and the kidney
Open Access
- 1 June 2007
- journal article
- review article
- Published by Elsevier in Kidney International
- Vol. 71 (12) , 1215-1222
- https://doi.org/10.1038/sj.ki.5002174
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) StudyAmerican Heart Journal, 2006
- Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic MechanismsNature Reviews Drug Discovery, 2005
- Statins Prevent Oxidized LDL-Induced Injury of Glomerular Podocytes by Activating the Phosphatidylinositol 3-Kinase/AKT-Signaling PathwayJournal of the American Society of Nephrology, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patientsClinical Nephrology, 2004
- Statins as antioxidant therapy for preventing cardiac myocyte hypertrophyJournal of Clinical Investigation, 2001
- Transcription factor-κB (NF-κB) and renal diseaseKidney International, 2001
- Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effectsKidney International, 2000
- Low-Density Lipoprotein-Induced Expression of Interleukin-6, a Marker of Human Mesangial Cell Inflammation: Effects of Oxidation and Modulation by LovastatinBiochemical and Biophysical Research Communications, 2000
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998